Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
Mice expressing either of the recessive autosomal mutations, lpr or gld,
develop autoimmune syndromes associated with massive lymphoid hyperplasia
and excessive autoantibody production. Since the range of autoantibody
specificities produced by these mice is similar to that of patients
afflicted with SLE and other systemic autoimmune diseases, they have been
considered a useful model for human disease. The lpr and gld mutations
have recently been mapped to the genes that encode the cell surface
molecules APO-1/Fas and Fas-ligand, respectively. Fas/Fas-ligand
interactions have been shown to be intimately involved in the apoptotic
pathways associated with calcium-independent T cell-mediated cytotoxicity
and peripheral T cell tolerance mechanisms associated with activation
induced cell death. Activated B cells also express the Fas antigen and
studies from this lab and others involving chimeric mice have shown that
in lpr/lpr B cells are inherently different from normal B cells, however
the actual role of Fas/Fas-ligand interactions in conventional B cells
responses is unexplored. The current proposal will address the role of
Fas/Fas-ligand in the regulation of conventional B cell immunity and
attempt to determine why normal B cell survival and function are
suppressed in an [lpr + wildtype] chimeric environment. These issues will
be addressed through the following specific aims: (1) Investigate how
different in vitro activation and cytokine signals regulate Fas and Fas-
ligand expression in T and/or B lymphocyte subpopulations and identify the
cells and conditions that are responsible for in vivo Fas-ligand
expression; (2) Determine the functional consequences of constitutive Fas
expression on B cell survival and function in lpr, gld and +/+ host
environments by producing and analyzing transgenic mice that inherit a B
lineage restricted Fas transgene; (3) Assess the functional properties of
lymphocytes from mice incapable of effectively expressing both Fas and
Fas-ligand, i.e. double mutant lpr/lpr gld/gld ice; and (4) Compare the
germinal center response of normal, lpr, and lpr beta2-microglobulin KO
mice with regard to magnitude, kinetics, antibody diversification, and
affinity maturation. The better understanding of the etiology of
autoimmunity gained from these studies should be directly applicable to
the treatment of human disease.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
B lymphocyteSCID mouseapoptosisautoantibodyautoimmune disordercell population studydisease /disorder modelgene expressiongene mutationgenetic straingenetically modified animalsimmunogeneticsimmunoregulationlaboratory mouseleukocyte activation /transformationleukopoiesissystemic lupus erythematosus
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
DUNS Number
604483045
UEI
FBYMGMHW4X95
Project Start Date
22-September-1986
Project End Date
31-March-2000
Budget Start Date
01-April-1997
Budget End Date
31-March-1998
Project Funding Information for 1997
Total Funding
$279,589
Direct Costs
$166,919
Indirect Costs
$112,670
Year
Funding IC
FY Total Cost by IC
1997
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$279,589
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AR035230-11
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AR035230-11
Patents
No Patents information available for 5R01AR035230-11
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AR035230-11
Clinical Studies
No Clinical Studies information available for 5R01AR035230-11
News and More
Related News Releases
No news release information available for 5R01AR035230-11
History
No Historical information available for 5R01AR035230-11
Similar Projects
No Similar Projects information available for 5R01AR035230-11